TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05892393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium Zr 89-DFO-YS5
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium Zr 89-DFO-YS5
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography / Computed Tomography (PET/CT)
Description: Positron emission tomography-computed tomography is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography scanner and an x-ray computed tomography scanner, to acquire sequential images from both devices in the same session, which are combined into a single superposed image

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography / Computed Tomography (PET/CT)
Description: Positron emission tomography-computed tomography is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography scanner and an x-ray computed tomography scanner, to acquire sequential images from both devices in the same session, which are combined into a single superposed image

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI)
Description: Positron emission tomography-magnetic resonance imaging is a hybrid imaging technology that incorporates magnetic resonance imaging soft tissue morphological imaging and positron emission tomography functional imaging.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI)
Description: Positron emission tomography-magnetic resonance imaging is a hybrid imaging technology that incorporates magnetic resonance imaging soft tissue morphological imaging and positron emission tomography functional imaging.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV
Study: NCT06419920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uneven terrain locomotor training
Description: The training will be comprised of up to 12 sets of 2-min continuous walking on an uneven terrain treadmill or mat, interspersed with rest breaks of at least one minute. Training will be completed three times per week for four weeks.
Study: NCT04925375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept is a selective costimulation modulator, inhibiting T lymphocyte activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Orencia solution supplied in a prefilled syringe should be refrigerated at 2C to 8C (36F to 46F). Orencia should not be used beyond the expiration date on the prefilled syringe. The product should be protected from light by storing in the original package until time of use. The prefilled syringe should not be frozen.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The composition of the placebo for Orencia is the same as the active study drug without the abatacept. The placebo will be packaged and labeled as described above for the Orencia prefilled syringes. To maintain the blind, injection volumes will be the same as the active treatment.
Study: NCT05711797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A 80mg
Description: ZX-7101A a drug to treatment influenza in Chinese adults

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A 80mg
Description: ZX-7101A a drug to treatment influenza in Chinese adults
Study: NCT06075277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631
Description: BI 1810631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631
Description: BI 1810631
Study: NCT04784143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midomafetamine
Description: 120 mg midomafetamine HCl followed by a supplemental dose of 60 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midomafetamine
Description: 120 mg midomafetamine HCl followed by a supplemental dose of 60 mg

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Manualized psychotherapy performed by therapist team

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Manualized psychotherapy performed by therapist team
Study: NCT06119204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oviva programme
Description: Total diet replacement for insulin-treated patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: NHS 12 week weight loss programme
Study: NCT05798585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block
Description: US guided ESP infiltration (saline solution vs Ropivacaine 0.375% according to randomization): unilateral injection of 0,4 ml kg -1 (ideal weight)2 under US guidance between the deep fascia of erector spinae muscle and the two transverse processes at the level of the 5th thoracic vertebrae. Duration approximately 10-15 minutes

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: ESP block
Description: US guided ESP infiltration (saline solution vs Ropivacaine 0.375% according to randomization): unilateral injection of 0,4 ml kg -1 (ideal weight)2 under US guidance between the deep fascia of erector spinae muscle and the two transverse processes at the level of the 5th thoracic vertebrae. Duration approximately 10-15 minutes
Study: NCT06570460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-beta estradiol
Description: Treatment with orally administered estrogen for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-beta estradiol
Description: Treatment with transdermally administered estrogen for 6 months
Study: NCT06570369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-624
Description: Oral dose, once daily for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose, once daily for 2 weeks
Study: NCT05603780

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: exploratory protocol
Description: physiological and cognitive evaluations
Study: NCT05280860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided bilateral rectus sheath block
Description: Bilateral RSB was guided by ultrasound before surgery after the completion of general anesthesia, First, the probe is placed transversely and perpendicular to reveal the anterior, hypoechoic, and posterior rectus sheath of the hyperechoic rectus abdominis. Moving the probe outward to reveal the sound images of the lateral margin of the rectus abdominis, external oblique, internal oblique, and transverse abdominis muscles. After the scanning, the needle was inserted from any segment of the probe under the guidance of real-time ultrasound; the tip reached between the rectus abdominis muscle and the posterior sheath of the rectus abdominis muscle. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct, If the needle tip was correctly positioned, 0.5 % ropivacaine 10 mL of local anesthetic was injected on each side. The same anesthesiologist was performed bilateral RSB under ultrasound guidance.
Study: NCT05390398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour change guided lifestyle intervention
Description: Participants in the intervention group receive personalized coaching from a lifestyle coach on adhering to the World Cancer Research Fund cancer prevention guidelines. The lifestyle coach is specialized in behaviour change techniques and uses these as the core of the lifestyle coaching. For each participant behavioural determinants will be assessed and targeted with specific applicable behaviour change techniques.
Study: NCT06556966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03020
Description: LY03020 for one single dose

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo for one single dose
Study: NCT05169268

Intervention type: DRUG
Intervention: ARIPiprazole Injection [Abilify]
Description: subject already receiving the combination of Abilify Maintena and Rexulti

Intervention type: DRUG
Intervention: Brexpiprazole
Description: subject already receiving the combination of Abilify Maintena and Rexulti
Study: NCT05934539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG.APV-527
Description: ALG.APV-527 is a human bispecific antibody in the ADAPTIR™ format with a silenced immunoglobulin 1 (IgG1) Fc domain targeting the co-stimulatory receptor 4-1BB, expressed on immune cells such as CD8+ T cells and natural killer (NK) cells, and the tumor associated antigen 5T4. ALG.APV-527 is being co-developed by Alligator Bioscience AB (Lund, Sweden) and Aptevo Therapeutics Inc. (Seattle, WA, USA) as a cancer immunotherapy.
Study: NCT04599166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Who Would You Choose: Serious Fun
Description: Who Would You Choose: Serious Fun is a conversation activity that prompts players (using scenarios and metaphors) to choose a spokesperson whose qualities are best suited to the role. At the end of the activity, players identify a real-life spokesperson based on the qualities considered during gameplay.
Study: NCT04912856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN496
Description: XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN496
Description: XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.
Study: NCT05914012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation based on Otago Exercise Program
Description: It took a total of 21 sessions, 7 days a week for 3 weeks. The sessions lasted 30 minutes. It is recommended to do exercises with comfortable shoes at least 1 hour after a meal. Each of his exercises will be videotaped and numbered and delivered to the intervention group via social networks and the Internet or by memory. In each exercise session, the physiotherapist followed the exercise sessions through social networks and answered questions from the older adults.
Study: NCT06476600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine injection
Description: All the eligible patients will undergo general anaesthesia for their elective surgeries (Laparoscopic Cholecystectomies). For the induction and maintenance of anaesthesia the participants will be randomised in a 1:1 ratio to receive either a standard opioid-based anaesthesia (by Nalbuphine) or opioid-free anaesthesia (by Dexmedetomidine) treatment protocols.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine Injection
Description: All the eligible patients will undergo general anaesthesia for their elective surgeries (Laparoscopic Cholecystectomies). For the induction and maintenance of anaesthesia the participants will be randomised in a 1:1 ratio to receive either a standard opioid-based anaesthesia (by Nalbuphine) or opioid-free anaesthesia (by Dexmedetomidine) treatment protocols.
Study: NCT05929053

Intervention type: OTHER
Group type: OTHER
Intervention: Vaccine Education Program Based on Integrated Change Model
Description: Vaccine Education Program Based on Integrated Change Model The training will take place in four sessions, one week apart, and each session will last approximately 45 minutes. The training will be carried out as group training with 4-5 people.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaccine Education Program Based on Integrated Change Model
Description: Vaccine Education Program Based on Integrated Change Model The training will take place in four sessions, one week apart, and each session will last approximately 45 minutes. The training will be carried out as group training with 4-5 people.
Study: NCT06235307

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: motivational interviewing
Description: Upon entry into the program, all patients will be seen for an assessment of their physical condition at the premises of Amiens Métropole by a teacher in adapted physical activity (APA) in order to be assessed and directed to a club or a approved associations. The EM group will also benefit from a motivational interview at 0 and 3 months by a doctor trained in the technique. The entire cohort will complete the SF12 (perception of quality of life) and IPAQ (current level of physical activity) questionnaires at 0 and 6 months during the usual appointments with the APA teacher.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: Upon entry into the program, all patients will be seen for an assessment of their physical condition at the premises of Amiens Métropole by a teacher in adapted physical activity (APA) in order to be assessed and directed to a club or a approved associations. The EM group will also benefit from a motivational interview at 0 and 3 months by a doctor trained in the technique. The entire cohort will complete the SF12 (perception of quality of life) and IPAQ (current level of physical activity) questionnaires at 0 and 6 months during the usual appointments with the APA teacher.
Study: NCT04945876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital follow-up
Description: Participants will receive:~One session of individual exercise and diet guidance focusing on goals and motivation.~An activity tracker and instructions on how to use it both for motivation, daily activity tracking, logging of specific exercise and using the wristbands heart rate monitor to control intensity level during exercise.~Monthly digital follow-up to provide support and address questions and goals regarding nutrition, daily energy expenditure and exercise.~Opportunity to send sms with questions regarding nutrition and exercise. Participants who are malnourished, or at risk of malnutrition will be offered a total of two hours of additional individualized, digital guidance on nutrition as needed.
Study: NCT06630416

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study: NCT06631820

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Epicatechin extract
Description: In the experimental phase, patients will take 50 mg of (-)- Epicatechin twice a day for 8 weeks (total dose 100mg/day). The nutraceutical will be supplied as monodose sachets from Aayam Therapeutics.Study participants will mix the sachet powder with juice (10-20mL) in the morning 15 minutes before breakfast and in the evening 15 minutes before sleeping or 1h after dinner.
Study: NCT06628999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Training
Description: 16-week training protocol focused on visual training designed for ameliorating cognitive performance and physical fitness

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: 16-week of active lifestyle based on healthy habits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Training-detraining
Description: 8-week training protocol focused on visual training designed for ameliorating cognitive performance and physical fitness, followed by 8 week with no specific training protocol
Study: NCT05741944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care with the use of PERSARC
Description: PERSARC is a personalized risk assessment tool which provides patients and STS professionals insight into the personalized risks and benefits of each treatment option based on patient's age, tumor size, tumor depth and histology. PERSARC will be used in multidisciplinary tumour boards to guide treatment advice and in consultation in which the oncological/orthopaedic surgeon informs the patient about his/her diagnoses and discusses the benefits and harms of all relevant treatment options

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: standard care
Description: All patients in control condition receive usual care.
Study: NCT06320756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wysa in Hindi
Description: Wysa in Hindi is a blended digital mental health intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual and group sessions on topics like motivation, coping, wellbeing
Description: Individual and group sessions on wellbeing, coping, and motivation with the diabetes educator team

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual and group sessions on topics like motivation, coping, wellbeing
Description: Individual and group sessions on wellbeing, coping, and motivation with the diabetes educator team
Study: NCT06208267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: This is a 3 arm RCT using the three dosage regimens mentioned above. Placebo doses will be provided for the 0, 8, 16 and 24 hours without TXA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: This is a 3 arm RCT using the three dosage regimens mentioned above. Placebo doses will be provided for the 0, 8, 16 and 24 hours without TXA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: This is a 3 arm RCT using the three dosage regimens mentioned above. Placebo doses will be provided for the 0, 8, 16 and 24 hours without TXA
Study: NCT06551129

Intervention type: DRUG
Intervention: Mavacamten
Description: As prescribed by treating physician
Study: NCT05690035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab & Fruquintinib
Description: combinational treatment of Tislelizumab and Fruquintinib until PD, intolerable toxicity, death or withdrawal of informed consent
Study: NCT04940325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1062a
Description: First infusion for 90 minutes and then infusion duration can be decreased to 30 minutes if participant didn't experience infusion related reactions (IRR)
Study: NCT06428851

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laser therapy
Description: Shoulder girdle muscles were lasered for 5 minutes a day, 3 days a week, total of 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrical nerve stimulation
Description: Neuromuscular electrical nerve stimulation was applied to the shoulder flexor and abductor muscles for 20 minutes a day 5 days a week, total of 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Classical physical therapy exercises were applied according to the patient's needs and neurologic level. These exercises are determined by the physiotherapist according to the functional status of the patient and consist of passive, passive assisted, active range of motion exercises, stretching and strengthening exercises, mobilization exercises 5 days a week for 1 hour, total of 4 weeks.
Study: NCT06126328

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Materna Prep Device
Description: Subjects are treated with Materna Prep Device prior to vaginal delivery
Study: NCT06416033

Intervention type: PROCEDURE
Intervention: Serum Irisin
Description: Measurement of plasma irisin level in leprosy patients.

Intervention type: PROCEDURE
Intervention: Serum Irisin
Description: Measurement of plasma irisin level in leprosy patients.
Study: NCT05739630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone liposome
Description: Mitoxantrone liposomes with 36mg/m2 and Bu 3.2mg/kg -5 to -4, Flu 30mg/m2 -12 to -9, Ara-C 1.5g/m2 -12 to -9，CTX 15mg/kg/d -3 to -2, was used as conditioning regimen, Post Transplant Cyclophosphamide 50 mg/kg IV daily on days +3 and +4.
Study: NCT06480409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR Mindfulness and Stress Reduction Program
Description: Intervention Procedure:~Duration and Frequency: Participants will engage in 15-minute VR relaxation sessions, held five times a week over a period of one month.~VR Content: The VR sessions will feature high-quality 360° videos with therapeutic audio, including guided relaxation, calming music, and nature sounds.~Physiological Monitoring: Throughout the sessions, participants' physiological responses will be monitored using Polar H-10 sensors to measure heart rate variability (HRV), providing data on autonomic nervous system activity.~Psychological Assessment: Participants will complete the Perceived Stress Scale (PSS-10) before and after the intervention to evaluate changes in stress levels.~Cybersickness Monitoring: The occurrence of any adverse effects, such as cybersickness, will be monitored and recorded.
Study: NCT05829174

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation and cognitive modules
Description: Psychoeducation and cognitive modules: what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation and cognitive modules
Description: Psychoeducation and cognitive modules: what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation and cognitive modules
Description: Psychoeducation and cognitive modules: what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral module: Starting on Time and Planning Realistically
Description: Learning of realistic planning, and timely starting of work.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral module: Working Time Restriction
Description: Restriction of allowed time for work, and gradual increase of allowed time, if previous time windows where effectively used.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral module: Pomodoro Time Management Technique
Description: Working in 25 minutes time intervals
Study: NCT05739630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: Control group:the conditioning regimen involved Ara-C 2g/m2 q12h -8, BU 3.2 mg/kg -7 to -5,CTX 1.8 g/m2 -4 to -3, to prevent GVHD, MTX 15mg/m2 +1d, 10mg/m2 +3,+6,+11,CsA 3mg/kg/d from -8d,MMF 1g q12h from -8d， ATG 2.5mg/kg/d -5 to -2.
Study: NCT06449898

Intervention type: OTHER
Group type: OTHER
Intervention: hemodialysis group
Description: Data were collected from patients undergoing treatment at a hemodialysis center in Kırşehir. Participants were informed about the study objectives and provided written consent. Data collection took approximately 20-30 minutes per participant and included a face-to-face interview where socio-demographic and clinical information was recorded.